⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 26, 2026HIV Medicine

Use of long‐acting cabotegravir and rilpivirine in people living with HIV : A prospective observational cohort study

Ana Codonal Alicia Lázaro Elena Martínez Alberto Delgado M.C. Durán Torralba

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effectiveness and safety of long-acting cabotegravir and rilpivirine in HIV treatment.
Prospective observational cohort design
Participants living with HIV
Monitoring of treatment outcomes and safety
Comparison to standard treatment approaches
CAB+RPV LA shows effectiveness as a treatment option
Safety profiles similar to other therapies
Durability of treatment outcomes observed over the study period

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

CAB+RPV LA appears to be an effective, safe and durable option for a switch strategy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Codonal et al. (2026) studied this question.

synapsesocial.com/papers/69c7722a8bbfbc51511e2788 https://doi.org/10.1111/hiv.70230

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed2024 · 31 citations
2Efficacy and Safety of Cabotegravir–Rilpivirine in PLWH: A Real-World Study2025 · 4 citations
3Real-World Experience with Long-Acting Injectable Cabotegravir/Rilpivirine in HIV Patients with Unsuppressed Viral Load2025 · 7 citations
4The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIVCohort Study · 2026 · 1 citations
5Two-year efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART studyCohort Study · 2026

More related papers

Safety, Tolerability, and Metabolic Effects of Long-Acting Cabotegravir and Rilpivirine in HIV Care: A Comprehensive Review2025
Long-acting cabotegravir and rilpivirine for the treatment of people with HIV: current landscape and challenges ahead2025
Brief Report: Switching to Long-Acting CAB/RPV: Data From an Italian Monocentric Cohort2024

More from HIV Medicine

Understanding community questions about HIV pre‐exposure prophylaxis ( PrEP ): A thematic analysis of reddit threads to inform development of an AI chatbot for PrEP educationTue,
Antiretroviral therapy intensification in people living with HIV on virological and clinical outcomes: A systematic reviewSun,